← Eichor
Condition: Mantle Cell Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Mantle Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymph
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04484012AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · 6 location(s) · LTZ Therapeutics, Inc. · NCT07121946ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT05992597Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07272499The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Alvaro Alencar, MD · NCT06029309Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT05724121CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 7 location(s) · British Columbia Cancer Agency · NCT06208735Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
NA · 1 location(s) · Peking University Third Hospital · NCT07257510Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
Phase 2 · 16 location(s) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ó · NCT07285590AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 · 4 location(s) · Newave Pharmaceutical Inc · NCT04775745Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Phase 1 · 1 location(s) · University of Colorado, Denver · NCT05098613Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT06054776Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Phase 2 · 3 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06553872CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 · 1 location(s) · Marcela V. Maus, M.D.,Ph.D. · NCT06026319IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05365659A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · New York Medical College · NCT04491370SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Phase 2 · 3 location(s) · Sun Yat-sen University · NCT07077512Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lympho
Phase 2 · 2 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07719556Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06464861Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lym
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06846489Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07199296Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.